Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Appoints Admiral Michael S. Rogers, Former NSA Director and Commander of U.S. Cyber Command, to Its Board of Directors15.9.2026 16:35:00 CEST | Press release
One of the nation's most senior cyber and intelligence leaders will help guide Innodata's strategy as it accelerates Federal and cyber-related AI initiatives. NEW YORK, NY / ACCESS Newswire / September 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced the appointment of Admiral Michael S. Rogers, U.S. Navy (Retired) - the former Director of the National Security Agency (NSA) and Commander of U.S. Cyber Command - to its Board of Directors, effective immediately. One of the highest-ranking cyber and intelligence leaders ever to serve the United States, Admiral Rogers joins at a pivotal moment, as the AI industry, enterprises and the Federal government alike wrestle with how to make increasingly capable AI systems safe and secure - and as Innodata accelerates its Federal practice launched last Fall and launches new capabilities designed specifically to make AI systems demonstrably safe and secure. "There is no one better positioned to help guide this chapter of Innodata's growth than
MicroVision Showcases Expanding Perception Portfolio at IAA Transportation 202615.9.2026 15:20:00 CEST | Press release
New Perception Platform, next-generation MOVIA S, HALO, FMCW technology, and commercial vehicle concept demonstrate MicroVision's Lidar 2.0 strategy in action REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 15, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, is showcasing the expanding breadth of its sensing and perception portfolio this week at IAA Transportation 2026, demonstrating how lidar hardware, perception software, and open sensor integration can work together to address increasingly complex applications across transportation and autonomy. At the center of MicroVision's IAA presence is the newly introduced MicroVision Perception Platform™, a flexible, modular architecture designed to allow sensing and perception configurations to be tailored to the requirements of individual applications. Throughout IAA, MicroVision is bringing that strategy to life through a series of technology demonstrations and reference concepts spanning pa
U.S. Polo Assn. Taps David Swetman as Global Design Lead, Men's and Boys' as Brand Targets $4 Billion in Global Retail Sales15.9.2026 13:00:00 CEST | Press release
Former Abercrombie & Fitch Menswear Leader Joins U.S. Polo Assn. to Advance Global Growth and Elevate Brand Worldwide WEST PALM BEACH, FL / ACCESS Newswire / September 15, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through over 1,200 retail stores worldwide, today announced the appointment of David Swetman as Global Design Lead, Men's and Boys', further strengthening the sports brand's Global Product Leadership Team as U.S. Polo Assn. continues its worldwide expansion and evolution. U.S. Polo Assn. continues to expand as one of the world's largest and fastest-growing sports brands, serving consumers globally through its extensive retail, e-commerce, and licensing network. The appointment reflects U.S. Polo Assn.'s continued global growth and strategic investment in world-class talent as the brand expands its product innovation, strengthens its c
MTech Mobility Appoints Rodney Moore as General Manager, Europe, to Accelerate Regional Growth15.9.2026 12:00:00 CEST | Press release
Seasoned technology executive brings more than 30 years of enterprise IT leadership to Dublin as MTech Mobility deepens its European commitment following Aer Lingus implementation win DUBLIN, IRELAND / ACCESS Newswire / September 15, 2026 / MTech Mobility today announced the appointment of Rodney Moore as General Manager, Europe. Moore, based in Dublin, will lead MTech Mobility's European operations, expand the regional team, and serve as the primary point of contact for the company's growing base of European customers. "Our European customers face challenges that demand more than a remote relationship - they need a partner who is present, accountable, and embedded in their landscape. Rodney's appointment is a direct investment in that commitment. His track record across Ireland and the UK means he understands exactly what European enterprises face, and he has the depth of experience to help them solve it. We are not just expanding our footprint; we are building the kind of trusted par
Chervon Names Matthew H. DeFeo as Senior Vice President of Sales, Training and Recruiting15.9.2026 00:00:00 CEST | Press release
Accomplished Power Tools and Outdoor Power Equipment industry leader brings decades of experience in sales leadership, talent recruitment and development, channel management, and key account alignment NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Matthew DeFeo joins Chervon as Senior Vice President of Sales, Training, and Recruiting effective September 14, 2026, reporting to CEO Joe Galli. Matthew DeFeo brings more than four decades of experience in the power tool and outdoor power equipment industry. He has an exceptional track record in building and leading large sales organizations, channel marketing teams, and training and development teams. DeFeo is widely recognized as a world-class leader in the campus recruiting of high potential graduates. He has built out impressive in-store sales coverage teams, end user marketing teams, campus recruiting teams, and training teams with an intense focus on key account alignment. A hallmark of DeFeo's remarkable career is his mentors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom